Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
APA
Tran PT, Wang JH, et al. (2025). Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(35), 3772-3773. https://doi.org/10.1200/JCO-25-01855
MLA
Tran PT, et al.. "Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.." Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 43, no. 35, 2025, pp. 3772-3773.
PMID
41043087
같은 제1저자의 인용 많은 논문 (2)
- Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008.
- Targeting TYRO3 attenuates apoptotic cell-driven cancer stemness in triple negative breast cancer.